Evidence to support use of palonosetron over generic serotonin type 3–receptor antagonists for chemotherapy-induced nausea and vomiting

Palonosetron, a serotonin type 3–receptor (5-HT3) antagonist, was approved by the Food and Drug Administration (FDA) in 2003 for the prevention of acute chemotherapy-induced nausea and vomiting (CINV) associated with initial and repeat courses of highly emetogenic chemotherapy (HEC) and moderately